IOVA - Despite Setback Iovance's Lifileucel Remains A Multibillion Dollar Prospect

• Iovance Biotherapeutics, in an attempt to secure FDA-approval for their biologic, lifileucel, in advanced melanoma, was set back as the FDA requires some more information.
• This can't come to much of a surprise to investors, as Iovance's TIL therapy carries a complex manufacturing and delivery process compared to your typical drug.
• While the company figures BLA submission will be pushed back to 2021, investors need not lose sight of what is likely to be a blockbuster biologic once it clears all hurdles.
• Iovance remains an interesting speculative biotechnology investment as it continues to advance TIL therapy into the market.

For further details see: